Investigation on PD-L1 biology for precise shaping of anticancer adoptive therapies
2019/35/D/NZ6/03073
Keywords
Descriptors
- NZ6_002: Immunologia kliniczna
- NZ6_001: Odporność swoista i nieswoista
Panel
NZ6 – Human and animal immunology and infection: immunity, immune disorders, immunotherapy, infectious and invasive diseases, microbiology, transplantology, allergology
Host institution
Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN
Voivodeship: mazowieckie
Principal investigator (from the host institution)
Number of co-investigators in the project: 4
Call
SONATA 15 – announced on 2019-09-16
- Amount awarded
- 1 624 380 PLN
- Project start date
- 2020-07-08
- Project end date
- 2025-07-07
- Project duration
- 60 months (the same as in the proposal)
- Project status
- Project completed
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.
- Authors:
- Malgorzata Bajor, Agnieszka Graczyk-Jarzynka, Katsiaryna Marhelava, Anna Burdzinska, Angelika Muchowicz, Agnieszka Goral, Andriy Zhylko, Karolina Soroczynska, Kuba Retecki, Marta Krawczyk, Marta Klopotowska, Zofia Pilch, Leszek Paczek, Karl-Johan Malmberg, Sébastien Wälchli, Magdalena Winiarska Radoslaw Zagozdzon
- Academic press:
- Journal for ImmunoTherapy of Cancer (year: 2022, volume: 10(1):e002500, pages: 39), Publisher: BMJ journals
- Status:
- Published
- DOI:
- 10.1136/jitc-2021-002500 – link to the publication